Nav: Home

Membrane fluidity influences sensitivity of ovarian cancer cell lines to auranofin

October 03, 2016

Increased fluidity in cell membranes could have a major impact on an ovarian cancer cell's sensitivity to treatment using the anti-rheumatic drug auranofin, research led by Plymouth University suggests.

Auranofin is currently undergoing trials for repurposing to treat recurrent epithelial ovarian cancer, which makes up around 90 per cent of diagnosed ovarian cancers.

A previous study, also led by Plymouth University, showed its use can reduce the survival rates of cancerous cells exhibiting depleted levels of BRCA1 gene (breast cancer 1, early onset).

Now new research, published in Mutation Research - Genetic Toxicology and Environmental Mutagenesis, has shown that increased fluidity within the cell membrane can enhance the ability of auranofin to induce increased DNA damage and cellular oxidation in these cells.

Cell membranes consist of a phospholipid bilayer, which protects a cell from its surroundings and controls the movement of substances.

Awadhesh Jha, Professor of Toxicology and Associate Head (Research) in the School of Biological Sciences, is the corresponding author of the study. He said: "Most traditional chemotherapeutic drugs act by damaging the DNA of cells, which leads to cell death. But in order to try and build resistance to this, cancer cells evolve by changing their genetic properties and cell membrane rigidity could be one of the confounding factors through which they become resistant to treatment. If a means to influence membrane fluidity could be achieved, it could enhance a drug's capability to cause DNA damage within cancer cells and significantly influence treatment outcomes."

The research was conducted by Dr Deepu Oommen and Dr Nicholas Dodd, from the Genetic Toxicology & Ecotoxicology Research Group at Plymouth University, on two common strains of ovarian cancer cell lines - IGROV1 and OVCAR5. They used cutting edge techniques to determine DNA damage and cell death, and electron spin resonance analysis to assess cell properties.

It showed that IGROV1 cells exhibited a more fluidised membrane compared to OVCAR5, were more sensitive to auranofin induced cytotoxicity and exhibited an increased number of DNA double strand breaks upon auranofin treatment.

Previous research has shown that chemo-resistant cancer cells demonstrate greater rigidity of the cell membrane, with the current study suggesting that greater uptake of auranofin could be influenced by increased membrane fluidity.

Its authors also say further studies should now be undertaken to identify ways to exploit the fluidic nature of the cancer cells so that they can be eliminated.
-end-


University of Plymouth

Related Breast Cancer Articles:

Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
Blood test offers improved breast cancer detection tool to reduce use of breast biopsy
A Clinical Breast Cancer study demonstrates Videssa Breast can inform better next steps after abnormal mammogram results and potentially reduce biopsies up to 67 percent.
Surgery to remove unaffected breast in early breast cancer increases
The proportion of women in the United States undergoing surgery for early-stage breast cancer who have preventive mastectomy to remove the unaffected breast increased significantly in recent years, particularly among younger women, and varied substantially across states.
Breast cancer patients with dense breast tissue more likely to develop contralateral disease
Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the contralateral breast, according to new research from The University of Texas MD Anderson Cancer.
Some early breast cancer patients benefit more from breast conservation than from mastectomy
Breast conserving therapy (BCT) is better than mastectomy for patients with some types of early breast cancer, according to results from the largest study to date, presented at ECC2017.
One-third of breast cancer patients not getting appropriate breast imaging follow-up exam
An annual mammogram is recommended after treatment for breast cancer, but nearly one-third of women diagnosed with breast cancer aren't receiving this follow-up exam, according to new findings presented at the 2016 Annual Clinical Congress of the American College of Surgeons.
Low breast density worsens prognosis in breast cancer
Even though dense breast tissue is a risk factor for breast cancer, very low mammographic breast density is associated with a worse prognosis in breast cancer patients.
Is breast conserving therapy or mastectomy better for early breast cancer?
Young women with early breast cancer face a difficult choice about whether to opt for a mastectomy or breast conserving therapy (BCT).
Breast density and outcomes of supplemental breast cancer screening
In a study appearing in the April 26 issue of JAMA, Elizabeth A.
Full dose radiotherapy to whole breast may not be needed in early breast cancer
Five years after breast-conserving surgery, radiotherapy focused around the tumor bed is as good at preventing recurrence as irradiating the whole breast, with fewer side effects, researchers from the UK have found in the large IMPORT LOW trial.

Related Breast Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".